Molecular Docking Studies of Thymoquinone and Its Analogues with Cyclooxygenase-2 (COX-2) for Screening Potential anti-Colorectal Cancer Compounds.

EasyChair Preprint no. 8929

Abstract

Colorectal cancer (CRC) is the third most common type of cancer, with over one million cases and 700,000 deaths reported each year (Siegel et al., 2020). Although the complex disease aetiology of CRC is still unknown, it is clear that genetic mutations and chronic inflammation are two potential causative factors. Surgery, chemotherapy or radiotherapy, immunotherapy, hormone therapy, and pharmacology are all options for treating CRC, depending on the tumour site and stage of the disease. Researchers are particularly interested in screening herbal plants, isolating, identifying, and evaluating their secondary metabolites as potential drug leads. Thymoquinone is a phytochemical compound found in the Nigella sativa plant. It's also found in Monarda plants. By using computational docking studies, we were able to investigate the inhibitory action of Thymoquinone and its derivatives on colorectal cancer in this study.

Keyphrases: 1.Colorectal, 2.cancer, 3.Docking Studies, 4.Thymoquinone, 5.COX2

@Booklet{EasyChair:8929,
  author = {Ranjit Kumar and Altaf Hussain and Nikita Yadav},
  title = {Molecular Docking Studies of Thymoquinone and Its Analogues with Cyclooxygenase-2 (COX-2) for Screening Potential anti-Colorectal Cancer Compounds.},
  howpublished = {EasyChair Preprint no. 8929},

  year = {EasyChair, 2022}}